New combo aims to control advanced breast cancer
Disease control
Recruiting now
This early-phase study tests the safety of combining two drugs, olaparib and estradiol, in post-menopausal women with advanced ER+/HER2- breast cancer that has spread. The goal is to find the best dose for future studies. Only 6 participants will be enrolled.
Phase: PHASE1 • Sponsor: Mary D Chamberlin • Aim: Disease control
Last updated May 06, 2026 16:03 UTC